InterSystemsتعين القائد السابق لهيئة الخدمات الصحية الوطنية (NHS) ومستشفى Mass General الدكتورTim Ferris لمنصب نائب الرئيس لممارسة الرعاية الصحية

 لاس فيغاس - الخميس, 12. مارس 2026 أيتوس واير طباعة 

 

(BUSINESS WIRE)-- أعلنت شركة InterSystems، وهي شركة رائدة في مجال تكنولوجيا البيانات الإبداعية وتدعم أكثر من مليار سجل صحي على مستوى العالم، اليوم عن تعيين Tim Ferris، الحاصل على دكتوراه في الطب، في منصب نائب الرئيس لشؤون ممارسات الرعاية الصحية. يأتي هذا الإعلان في الوقت الذي يجتمع فيه قادة الرعاية الصحية لحضور مؤتمر ومعرض HIMSS العالمي للصحة لعام 2026.

في هذا المنصب، سيستفيد الدكتور Ferris من رؤيته الشاملة للصناعة للمساعدة في توجيه المسار السريري والاستراتيجي لحلول الرعاية الصحية للشركة في جميع أنحاء العالم. بالاستناد إلى خبرته الواسعة، سيعمل كمستشار استراتيجي لأنظمة الصحة العالمية والحكومات، وسيقوم بتصميم حلول تكنولوجية موجهة بناءً على احتياجات المديرين التنفيذيين في العالم الحقيقي، وسيعمل على تطوير أبحاثه الأكاديمية حول بنية بيانات الصحة، وسيقود الحوار العام حول تقاطع الذكاء الاصطناعي وتقديم الرعاية.

يُضفي الدكتور Ferris منظورًا عالميًا فريدًا على شركة InterSystems لا مثيل له تقريبًا في مجال الرعاية الصحية. تمتد مسيرته المهنية على مدى 30 عامًا كطبيب ممارس للرعاية الصحية الأولية، وقيادة تنفيذية في أنظمة صحية أمريكية مرموقة، وحوكمة تكنولوجية على المستوى الكلي لحكومة المملكة المتحدة، واحتضان شركات ناشئة في مجال تكنولوجيا الصحة القائمة على الذكاء الاصطناعي.

قال Don Woodlock، رئيس شركة InterSystems: "قلة قليلة من القادة في العالم نظروا إلى الرعاية الصحية من العديد من وجهات النظر الحاسمة مثل الدكتور Ferris. لقد عالج Tim المرضى كطبيب في الخطوط الأمامية، وأشرف على آلاف الأطباء في أحد أكثر أنظمة المستشفيات احترامًا في العالم، ووجه السياسة الصحية الوطنية في المملكة المتحدة، واحتضن شركات ناشئة متطورة في مجال الذكاء الاصطناعي. هذه التجارب تجعله القائد المثالي للمساعدة في تصميم حلول تكنولوجية فعالة حقًا لجميع أصحاب المصلحة في النظام البيئي للرعاية الصحية".

في الآونة الأخيرة، شغل الدكتور Ferris منصب رئيس الرعاية الصحية في Red Cell Partners، وهي شركة حاضنة للتكنولوجيا وشركة استثمار. قبل ذلك، وبصفته المدير الوطني للتحول في هيئة الخدمات الصحية الوطنية في إنجلترا NHS))، أدار ميزانية قدرها 2.5 مليار دولار وقاد تسريعًا هائلاً للرقمنة في الخطوط الأمامية. وشملت فترة ولايته توسيع تطبيق NHS)) لخدمة أكثر من 40 مليون مواطن، ونقل خدمات البيانات الوطنية إلى السحابة، وتسهيل اتفاقيات البيانات الرائدة مع شركات التكنولوجيا والتكنولوجيا الحيوية العالمية الرائدة.

قبل عمله التحويلي مع هيئة الخدمات الصحية الوطنية NHS))، شغل الدكتور Ferris منصب الرئيس التنفيذي ورئيس مجلس إدارة منظمة أطباء ماساتشوستس العامة ونائب الرئيس الأول لصحة السكان في مستشفى Mass General بريغهام. في تلك الأدوار، أشرف على 3000 طبيب وقاد منظمة رعاية مسؤولة حققت أعلى أداء وطني في مقاييس الجودة مع تحقيق وفورات تراكمية في التكاليف تزيد عن مليار دولار لدافعي الضرائب.

أصبح الدكتور Ferris، وهو قائد معترف به في مجال تكنولوجيا المعلومات الصحية وطبيب متدرب في جامعة هارفارد، أستاذًا للطب في جامعة هارفارد في عام 2018. قام بتأليف أكثر من 120 منشورًا حول قياس الجودة وتكنولوجيا المعلومات الصحية وصحة السكان، ويعمل حاليًا في دور استشاري لجامعة ستانفورد.

 حول InterSystems

تقدم شركة InterSystems، وهي شركة رائدة في مجال تكنولوجيا البيانات الإبداعية، أساسًا موحدًا لتطبيقات الجيل القادم لعملاء الرعاية الصحية والتمويل والتصنيع وسلسلة التوريد في أكثر من 80 دولة. تعمل منصات البيانات الخاصة بنا على حل مشكلات قابلية التشغيل البيني والسرعة وقابلية التوسع للمؤسسات الكبيرة في جميع أنحاء العالم لإطلاق العنان لقوة البيانات والسماح للأشخاص بإدراك البيانات بطرق مبتكرة. تأسست InterSystems في عام 1978، وهي ملتزمة بالتميز من خلال دعمها على مدار الساعة طوال أيام الأسبوع للعملاء والشركاء في جميع أنحاء العالم. تمتلك InterSystems التي يملكها القطاع الخاص ومقرها في بوسطن، بولاية ماساتشوستس، 38 مكتبًا في 28 دولة حول العالم. لمزيد من المعلومات، يرجى زيارة InterSystems.com.

إن نص اللغة الأصلية لهذا البيان هو النسخة الرسمية المعتمدة. أما الترجمة فقد قدمت للمساعدة فقط، ويجب الرجوع لنص اللغة الأصلية الذي يمثل النسخة الوحيدة ذات التأثير القانوني.

 

الرابط الثابت

https://www.aetoswire.com/ar/news/54440997

جهات الاتصال

 للتواصل مع قسم العلاقات العامة في شركة InterSystems:

Zach Keating

 pr@intersystems.com

 617-551-5158

1NCE and Netmore Combine Cellular and LoRaWAN Access to Deliver Global IoT Coverage

COLOGNE, Germany & STOCKHOLM - Wednesday, 11. March 2026

• The two largest global providers of massive IoT networks partner to provide a combined offering of LoRaWAN^® and Cellular connectivity.
• 1NCE now integrates Netmore’s LoRaWAN into the 1NCE OS platform, allowing customers to use both services seamlessly through its software stack.
• The new network addresses 90% of the LPWAN market and offers an unparalleled ability to eliminate coverage blind spots around the globe

 

(BUSINESS WIRE)--1NCE, a company offering a plug-and-play platform for creating and managing the world’s best IoT products, today opened access for its customers to the LoRaWAN^® services of Netmore, the world’s leading low power wide area network operator for massive IoT. With growing demand for low power long range connectivity, the Netmore LoRaWAN Network Server (LNS) Plugin provides 1NCE customers access to cellular and LoRaWAN IoT coverage options through one platform.

The launch of the Netmore Plugin marks the beginning of strategic collaboration to expand the combined offering of the two biggest massive IoT network specialists — 1NCE, the biggest private IoT network in the cloud and Netmore, the largest LoRaWAN network and platform provider in the world. 1NCE’s software and connectivity platform has become a new industry standard.

Working together to support their respective customer bases with both cellular and LoRaWAN technology delivers a powerful layer of redundancy to cover the hardest to reach spots with reliable connectivity and IoT services. Through a unified visibility, ingestion and routing software tool, it’s now possible to seamlessly manage both technologies in one place. It’s ideal for use cases such as smart cities, street lighting, logistics, smart metering and other utility applications. An estimated 90% of the market can be served by LPWAN and LoRaWAN by 2028, as forecasted by global technology research and advisory firm Omdia¹.

“Cellular plus LoRaWAN is an unbeatable package that delivers the best value in IoT,” said Ivo Rook, Co-Chief Executive Officer of 1NCE. “By combining our market-leading LoRaWAN services with 1NCE’s cellular platform, customers can now eliminate coverage gaps, reduce complexity, and deploy low-bandwidth solutions with unprecedented reliability across the world,” said Ove Anebygd, Chief Executive Officer of Netmore Group.

The Netmore’s LoRaWAN Plugin is now available on the 1NCE platform.

¹"Low Power Wide Area Network (LPWAN) Market Report – 2023 Data", Omdia

About 1NCE

1NCE delivers the fundamental software and connectivity platform for customers to create and manage the world’s best intelligent products. The software platform enables customers to easily, securely and reliably collect device data across 170+ countries and turn it into actionable intelligence.

About Netmore

Netmore Group is the leading global network operator for Massive IoT, powering the world’s most advanced and sustainability-focused solutions for utilities, buildings, cities, and other markets that benefit from sensor-connected environments. Netmore operates in 18 countries and is backed by Nordic infrastructure investor Polar Structure.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260311190961/en/

Permalink
https://www.aetoswire.com/en/news/1103202653766

Contacts

Media Contact
1NCE: press@1NCE.com
Netmore: ken.lynch@netmoregroup.com

Galderma Completes Successful Placement of EUR 500 Million Eurobond

 ZUG, Switzerland - Wednesday, 11. March 2026

(BUSINESS WIRE)--Galderma Group AG (SWX:GALD):

NOT FOR DISTRIBUTION IN THE UNITED STATES OR IN ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD BE RESTRICTED BY APPLICABLE LAW OR REGULATION.

Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced the successful placement of a single-tranche EUR 500 million Eurobond. The bond has a 5-year maturity and carries a fixed-rate annual coupon of 3.375%.

The Eurobond was placed on March 10, 2026, with settlement expected on March 17, 2026, and will be listed on the SIX Swiss Exchange.

Citigroup, ING, J.P. Morgan and RBC Capital Markets jointly led the transaction.

Net proceeds from the transaction will be used to fully repay Galderma’s existing bank term loan issued in connection with the company’s initial public offering in March 2024. The transaction represents the final step in Galderma’s refinancing process, having obtained two investment grade credit ratings.

Galderma is currently rated ‘BBB’ (stable outlook) by Fitch and ‘BBB’ (positive outlook) by S&P Global Ratings (S&P), and the new bond is expected to be rated ‘BBB’ by both agencies.

The successful issuance is leverage-neutral and is not expected to materially affect Galderma’s full-year 2026 guidance for net financial expenses.

About Galderma

Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

Forward-looking statements

Certain statements in this announcement are forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as "plans", "targets", "aims", " believes", "expects", "anticipates", "intends", "estimates", "will", "may", "continues", "should" and similar expressions. These forward-looking statements reflect, at the time, Galderma's beliefs, intentions and current targets/ aims concerning, among other things, Galderma's results of operations, financial condition, industry, liquidity, prospects, growth and strategies and are subject to change. The estimated financial information is based on management's current expectations and is subject to change. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial consequences of the plans and events described herein. Actual results may differ from those set forth in the forward-looking statements as a result of various factors (including, but not limited to, future global economic conditions, changed market conditions, intense competition in the markets in which Galderma operates, costs of compliance with applicable laws, regulations and standards, diverse political, legal, economic and other conditions affecting Galderma’s markets, and other factors beyond the control of Galderma). Neither Galderma nor any of their respective shareholders (as applicable), directors, officers, employees, advisors, or any other person is under any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You should not place undue reliance on forward-looking statements, which speak of the date of this announcement. Statements contained in this announcement regarding past trends or events should not be taken as a representation that such trends or events will continue in the future. Some of the information presented herein is based on statements by third parties, and no representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, reasonableness, accuracy, completeness or correctness of this information or any other information or opinions contained herein, for any purpose whatsoever. Except as required by applicable law, Galderma has no intention or obligation to update, keep updated or revise this announcement or any parts thereof.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260310353940/en/


Permalink
https://www.aetoswire.com/en/news/1103202653759

Contacts
For further information:

Media

Christian Marcoux, M.Sc.
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50

Richard Harbinson
Corporate Communications Director
richard.harbinson@galderma.com
+41 76 210 60 62

Investors

Emil Ivanov
Head of Strategy, Investor Relations and ESG
emil.ivanov@galderma.com
+41 21 642 78 12

Jessica Cohen
Investor Relations and Strategy Director
jessica.cohen@galderma.com
+41 21 642 76 43

 

Andersen Consulting Strengthens Platform with Collaborating Firm Ambit Iberia

 

(BUSINESS WIRE)--Andersen Consulting expands its technology and business transformation capabilities through a Collaboration Agreement with Ambit Iberia, a consulting firm specializing in digital and regulatory solutions for the life sciences sector.

Founded in 2003 and headquartered in Spain, Ambit Iberia provides integrated consulting, technology, and talent solutions for pharmaceutical, biotechnology, and medical device companies. The firm supports clients in meeting evolving quality, compliance, and regulatory standards through services spanning regulatory affairs, data integrity, IT system validation, and digital transformation. Leveraging more than 20 years of industry expertise, Ambit Iberia also offers human capital and executive search services that connect organizations with specialized professionals and senior talent, enhancing efficiency and driving sustainable growth in a highly regulated environment.

“Our focus has always been on delivering specialized consulting and technology services that help pharmaceutical, medical device and biotech companies to meet the highest standards of quality and compliance,” said Brismark Antoniony Díaz, managing director of Ambit Iberia. “Collaborating with Andersen Consulting marks a pivotal step in that journey, empowering us to scale our capabilities globally and deliver the same level of excellence, compliance, and technical expertise to clients around the world.”

Global Chairman and CEO of Andersen Mark L. Vorsatz added, “Ambit Iberia embodies the innovation and precision required in today’s life sciences landscape. The firm’s expertise and commitment to regulatory excellence enhance their ability to provide multidisciplinary consulting services that connect strategy, technology, and human capital. These capabilities complement our organization’s global platform and broaden the value we deliver to clients worldwide.”

Andersen Consulting is a global consulting practice providing a comprehensive suite of services spanning corporate strategy, business, technology, and AI transformation, as well as human capital solutions. Andersen Consulting integrates with the multidimensional service model of Andersen Global, delivering world-class consulting, tax, legal, valuation, global mobility, and advisory expertise on a global platform with more than 50,000 professionals worldwide and a presence in over 1,000 locations through its member firms and collaborating firms. Andersen Consulting Holdings LP is a limited partnership and provides consulting solutions through its member firms and collaborating firms around the world.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260311056525/en/

Permalink

https://www.aetoswire.com/en/news/1103202653775

Contacts

mediainquiries@Andersen.com

 

شركة Haleon تعزز التزامها تجاه الصين في ظل تركيز المستهلكين على تحسين صحتهم اليومية

 شنغهاي -

استثمار بقيمة 65 مليون جنيه إسترليني في مصنع جديد لتصنيع منتجات العناية بصحة الفم في شنغهاي بهدف دفع عجلة النمو في أكبر سوق عالمي لصحة اللثة

تسعى شركة Haleon إلى توسيع انتشار العلامة التجارية لصحة اللثة parodontax لتشمل 30 مدينة صينية بحلول نهاية عام 2027، بما في ذلك المدن الأسرع نموًا، للوصول إلى المتسوقين الطموحين داخل المتاجر والمنصات الإلكترونية

مذاق مُعدّ خصوصًا، ورغوة أكثر كثافة، وتغليف فاخر لجذب المستهلكين المحليين

 

(BUSINESS WIRE)-- تعمد شركة Haleon، الاستهلاكية التي ينصب تركيزها على تحسين الصحة اليومية، إلى ضخ استثمار بقيمة 65 مليون جنيه إسترليني في موقع جديد ومتطور لتصنيع منتجات صحة الفم في شنغهاي. ستدعم هذه المنشأة خطة توسيع محفظة الشركة لمنتجات العناية بصحة الفم، والتي تضم العلامتين التجاريتين العالميتين Sensodyne وparodontax، في مدن الصين من المستوى الثاني والثالث سريعة النمو، حيث تسهم زيادة الدخل، وارتفاع الوعي بالصحة اليومية، والتحول نحو المنتجات الموثوقة ذات العلامات التجارية المعروفة، في إعادة تشكيل سلوك المستهلكين.

في إطار هذا التحول، أصبح قطاع أكبر من المستهلكين يدرج العناية الوقائية بصحة الفم ضمن الروتين اليومي للعناية الذاتية، فيما يشهد الطلب على الحلول المتميزة المدعومة علميًا تسارعًا فائقًا. ثم إنَّ هذا الاستثمار من شأنه تعزيز حضور Haleon في عالم الصناعة المحلية، ويرتقي بالشركة إلى مكانة رائدة ويزودها بالإمكانات اللازمة التي تمكنها من الاستفادة من فرص النمو طويلة الأجل في أحد أكثر أسواقها ديناميكية.

يُعدّ سوق صحة اللثة في الصين الأكبر عالميًا، حيث تُقدّر قيمته بنحو 860 مليون جنيه إسترليني. ففي ظل معاناة أكثر من 70% من البالغين في الصين من أحد أشكال مشاكل اللثة، وتنامي الوعي بالأعراض، مثل النزيف والاحمرار والحساسية، تبرز فرص سوقية هائلة لمنتجات صحة اللثة المثبتة سريريًا.

تعدّ parodontax، أسرع علامات Haleon التجارية نموًا في مجال صحة الفم، فهو أول معجون أسنان في الصين يثبت سريريًا قدرته على معالجة السبب الجذري لنزيف اللثة، إذ يعمل على إزالة البلاك المتراكم، الذي يُعدّ أحد الأسباب الرئيسية لأمراض اللثة. ومع ذلك، فإنَّ خصائصه الحسية المميزة، الناتجة عن مكونه النشط الرئيسي "بيكربونات الصوديوم"، تختلف عن العديد من معاجين الأسنان المحلية التي عادةً ما تتمتع بنكهات أكثر حلاوة أو نكهات الزهور.

لضمان توافق المنتج مع أذواق المستهلكين الصينيين، تعاون فريق البحث والتطوير العالمي في Haleon تعاونًا وثيقًا مع علماء الحواس المحليين لتكييف النكهة، حيث تم تحقيق التوازن بين فعالية التركيبة العالمية وبين إضافة لمسات أكثر حلاوة وعطرية، مع توفير تجربة تنظيف ذات رغوة أعلى، كل ذلك في ظل الحفاظ على كفاءة الأداء السريري للمنتج. أما التغليف الفاخر، فإنه يسلط الضوء أيضًا على فوائده العلاجية المثبتة سريريًا، في ظل التطور المتزايد الذي يشهده سوق العناية بالفم.

تعتمد Haleon أيضًا إستراتيجية بيع بالتجزئة متعددة القنوات لتيسير سبل وصول معجون parodontax إلى مختلف أنحاء الصين، وإلى جانب حضورها المتنامي سريع الوتيرة على منصات التجارة الإلكترونية مثل Douyin، تهدف الشركة إلى تعزيز آليات توزيع معجون parodontax ليشمل 30 مدينة بحلول نهاية عام 2027، ليصل المنتج بذلك إلى أكثر من 250 مليون شخص، إذ تُعدّ هذه المدن موطنًا لطبقة متوسطة متنامية ذات دخل متزايد وتحدوها رغبة قوية في اقتناء العلامات التجارية الدولية الموثوقة. وتجدر هنا الإشارة إلى أنَّ متاجر التجزئة الكبرى (التي تعتمد نظام العضوية) تشهد توسع متسارع، في الوقت الذي تحافظ فيه Haleon على حضور راسخ في صيدليات البيع بالتجزئة، بنوعيها الواقعي والإلكتروني، بدعم من شبكة من أخصائيي طب الأسنان الذين يوصون بمنتجاتها بانتظام.

 صرح Brian McNamara، المدير التنفيذي لشركة Haleon، قائلاً: "تمثل الصين أولوية إستراتيجية لشركة Haleon. واستنادًا إلى قدراتنا الراسخة في البحث والتطوير وفريقنا المحلي القوي، يعكس هذا الاستثمار التزامنا طويل الأمد بنقل أفضل ما لدينا من علوم وابتكارات عالمية لتحسين صحة ورفاهية المستهلكين الصينيين".

"وعن طريق دمج خبرتنا البحثية العالمية مع رؤى محلية متعمقة وقدرات التصنيع والبحث والتطوير الميدانية، فنحن نقدم منتجات عالية الجودة ومدعومة علميًا تعمل على تحسين الصحة اليومية في الصين."

ستقع منشأة العناية بصحة الفم الجديدة في منطقة لينغانغ الجديدة بمدينة شنغهاي، والتي تُعدّ مركزًا صناعيًا سريع النمو، وعن طريق توفير القدرة الإمدادية للسوق الصينية داخليًا، تهدف Haleon إلى الاستجابة بسرعة أكبر لتفضيلات المستهلكين المتغيرة ودفع عجلة الابتكار في فئة سريعة النمو، داعمةً بذلك طموحها المتمثل في الوصول إلى مليار مستهلك إضافي بحلول عام 2030، في ظل تحقيق وفورات إجمالية ناجمة عن تحسين الإنتاجية بقيمة 800 مليون جنيه إسترليني في غضون السنوات الخمس المقبلة عبر سلسلة إمداد أكثر مرونة وكفاءة.

في يونيو 2025، أكملت Haleon أيضًا صفقة الاستحواذ الكامل على مشروعها المشترك TSKF باستثمار يقارب 700 مليون جنيه إسترليني، لتمسك بذلك زمام السيطرة على أعمالها في مجال الأدوية التي لا تستلزم وصفة طبية في الصين. أضف إلى ذلك أنَّ هذه الاستثمارات مجتمعة تؤكد ثقة Haleon طويلة الأجل بنمو سوق الرعاية الصحية الاستهلاكية في الصين.

 نبذة عن Haleon

تُعدّ Haleon (بورصة لندن/بورصة نيويورك: HLN) شركة استهلاكية ينصب تركيزها على تحسين الصحة اليومية، فكوادرنا البشرية، وعلاماتنا التجارية، وأبحاثنا، واستثماراتنا، وابتكاراتنا؛ كلها تهدف إلى تحسين الصحة اليومية للمستهلكين. كما تشمل محفظة منتجاتنا ست فئات رئيسية، هي: العناية بصحة الفم، والفيتامينات والمعادن والمكملات الغذائية، ومسكنات الألم، وصحة الجهاز التنفسي، وصحة الجهاز الهضمي، والعناية العلاجية بالبشرة، وفئات أخرى. هذا، وتحظى علاماتنا التجارية المتميزة، مثل Advil وCentrum وOtrivin وPanadol وparodontax وPolident وSensodyne وTheraflu وVoltaren، بثقة أكثر من مليار مستهلك، ويوصي بها المتخصصون في مجال الرعاية الصحية على مستوى العالم.

 لمزيد من المعلومات، الرجاء زيارة www.haleon.com.

إن نص اللغة الأصلية لهذا البيان هو النسخة الرسمية المعتمدة. أما الترجمة فقد قدمت للمساعدة فقط، ويجب الرجوع لنص اللغة الأصلية الذي يمثل النسخة الوحيدة ذات التأثير القانوني.

صور / وسائط متعددة متوفرة على : https://www.businesswire.com/news/home/20260311389622/en

 

الرابط الثابت

https://aetoswire.com/ar/news/544442741

جهات الاتصال

 المسؤول الإعلامي في Haleon:

 Gemma Thomas

 البريد الإلكتروني: gemma.x.thomas@haleon.com

 الهاتف: ‎+44 (0) 7985 175048

Laserfiche Earns 5-Star Rating in the 2026 CRN® Partner Program Guide

 LONG BEACH, Calif. - Wednesday, 11. March 2026 AETOSWire 

(BUSINESS WIRE)--Laserfiche — the leading SaaS provider of intelligent content management — has been honored by CRN®, a brand of The Channel Company, with a 5-Star Award in the 2026 CRN Partner Program Guide. This annual guide is an essential resource for partners seeking vendor partner programs that match their business goals and deliver high partner value.

As organizations navigate growing pressure to increase productivity and respond to regulatory change, Laserfiche’s AI-powered document management solutions enable users to transform operations and achieve meaningful business results at scale.

Partners that innovate with Laserfiche solutions have the opportunity to grow profits through the Laserfiche Partner Program, which equips them with the tools and resources needed to deliver customer success. Laserfiche’s partner ecosystem drives sustainable growth, delivers differentiated solutions and maximizes opportunities for both partners and their customers. Laserfiche provides comprehensive AI and cloud-deployment training resources that empower partners to identify opportunities, secure deals and deliver effective solutions with confidence.

“We are committed to equipping our partners with the comprehensive educational and marketing resources that enable them to secure profitable deals and provide transformative solutions,” said Josep Domingot, vice president of sales at Laserfiche. “A 5-star rating in the CRN Partner Program Guide certifies the work Laserfiche has done to create an expansive and profitable channel ecosystem.”

For the 2026 Partner Program Guide, the CRN research team assessed technology vendors based on the strength and breadth of their partner program offerings, including partner training and enablement, pre‑ and post‑sales support, marketing resources, technical assistance and ongoing communication. The resulting guide provides partners with meaningful insight into partner programs designed to support sustained success in a rapidly evolving channel landscape.

“Being included in the 2026 CRN Partner Program Guide reflects how today’s technology vendors are rethinking their partner programs to keep pace with a rapidly evolving channel,” said Jennifer Follett, VP, U.S. Content, Executive Editor, CRN, at The Channel Company. “As solution providers navigate new customer demands, business models and technologies, this annual guide serves as a critical resource for identifying vendors that are investing in programs designed to drive long‑term growth and shared success. The guide delivers meaningful insight into what sets each partner program apart, helping solution providers make confident, strategic partnership decisions.”

See the 2026 Partner Program Guide at www.CRN.com/PPG. To learn more about the Laserfiche Partner Program, visit the Laserfiche website.

About Laserfiche

Laserfiche is a leading enterprise platform that helps organizations digitally transform operations and manage their content with AI-powered solutions. Through scalable workflows, customizable forms, no-code templates and AI-enabled capabilities, the Laserfiche® document management platform accelerates how business gets done. Trusted by organizations of all sizes — from startups to Fortune 500 enterprises — Laserfiche empowers teams to boost productivity, foster collaboration, and deliver a superior customer experience at scale. Headquartered in Long Beach, California, Laserfiche operates globally, with offices across North America, Europe, and Asia.

Connect with Laserfiche: Laserfiche Blog | X | LinkedIn | Facebook

About The Channel Company:

The Channel Company (TCC) is the global leader in channel growth for the world's top technology brands. We accelerate success across strategic channels for tech vendors, solution providers, and end users with premier media brands, integrated marketing and event services, strategic consulting, and exclusive market and audience insights. TCC is a portfolio company of investment funds managed by EagleTree Capital, a New York City-based private equity firm. For more information, visit thechannelco.com.

Follow The Channel Company: X, LinkedIn and Facebook.

© 2026 The Channel Company, Inc. CRN is a registered trademark of The Channel Company, Inc. All rights reserved.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260311840090/en/

Permalink

https://www.aetoswire.com/en/news/1103202653776

Contacts

Linda Domingo

Communications Director, Laserfiche

Linda.domingo@laserfiche.com

562-988-1688 ext. 234

The Channel Company Contact:

Natalie Lewis

The Channel Company

nlewis@thechannelcompany.com

 

Xsolla Releases New Industry Report Identifying the Biggest Opportunities for the Future of Video Games for Developers

 LOS ANGELES 

The Xsolla Report Reveals How Studios Are Unlocking New Revenue, Reaching Global Audiences, and Building Durable Competitive Advantages

 

(BUSINESS WIRE)--Xsolla, a leading global video game commerce company, today released the latest edition of The Xsolla Report, timed to coincide with this week's activations and collaborations in San Francisco. This edition provides insights from working with thousands of studios to map out where the industry’s biggest opportunities are emerging.

The gaming industry remains extraordinarily vibrant, and the playbook for success is changing. Studios that are adapting their commercial strategies, embracing direct-to-player commerce, expanding into high-growth global markets, and leveraging AI to sharpen operations are pulling ahead and building businesses designed to thrive for years to come.

"The economics of game development have and will continue to shift and evolve into the future. Budgets have expanded, player acquisition costs have surged, and traditional publishing models are under increasing strain," said Chris Hewish, President of Xsolla. "We have reached a tipping point where old assumptions no longer hold, and leaders who recognize this shift early will capture disproportionate advantage."

"The conversation around direct-to-consumer in gaming has fundamentally changed coming out of multiple regulatory changes," said Berkley Egenes, Chief Marketing and Growth Officer at Xsolla. "What began as a tactical revenue diversification play has evolved into a strategic imperative for studios to grow and thrive into the future of live-service games.“

Key Findings From The Xsolla Report Include:

Leading game companies are already generating 15–45% of total revenue through D2C web shops, yielding up to 25% more profit per transaction compared to platform-based purchases

High-growth markets like Turkey (13% CAGR), India (11%), and Southeast Asia (6%) represent the industry's most exciting expansion opportunities through 2029

AI is delivering real operational gains, compressing development timelines by roughly 20% and reducing support costs by approximately 40%

"Platform omnivore" gamers who play across consoles, PC, and mobile now represent 43% of US gamers, up from 30%, creating new pathways for studios to reach players wherever they are

Titles with sustainable live service models continue to grow, with PUBG: Battlegrounds reaching approximately 75 million Steam users and Roblox on Xbox climbing to nearly 30 million owners

The April 2025 U.S. court ruling allowing in-app linking to external offers has opened the door for developers to engage players across channels like never before

The report also outlines a clear roadmap for what leaders should prioritize next: building for modularity and faster development cycles, investing in owned audience infrastructure, and turning compliance into a competitive advantage as global markets open up.

"We're entering a period where the studios with strong foundational commercial infrastructure will outperform those with superior creative execution alone," added Egenes. "D2C is becoming a table-stakes requirement for ambitious live-service games, and the studios that treat this moment as strategic will be the ones defining the future of mobile gaming success."

The full Xsolla Report is available for download at: xsolla.pro/xsolla-report-v9.

About Xsolla

Xsolla is a global commerce company with robust tools and services to help developers solve the inherent challenges of the video game industry. From indie to AAA, companies partner with Xsolla to help them fund, distribute, market, and monetize their games. Grounded in the belief in the future of video games, Xsolla is resolute in the mission to bring opportunities together, and continually make new resources available to creators. Headquartered and incorporated in Los Angeles, California, Xsolla operates as the merchant of record and has helped over 1,500+ game developers to reach more players and grow their businesses around the world. With more paths to profits and ways to win, developers have all the things needed to enjoy the game.

For more information, visit xsolla.com.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260311021020/en/

Permalink

https://www.aetoswire.com/en/news/1103202653773

Contacts

Media Contact

Derrick Stembridge

Vice President of Global Public Relations, Xsolla

d.stembridge@xsolla.com

 

NTT DATA Unveils NVIDIA-Powered Enterprise AI Factories to Support Secure AI Adoption and Help Clients Drive Measurable ROI

TOKYO & LONDON - Wednesday, 11. March 2026

NTT DATA drives success in healthcare, manufacturing and other sectors with NVIDIA-powered technologies

NTT DATA AI solutions now integrate NVIDIA AI Enterprise software, including NVIDIA NeMo and NIM Microservices to create a full-stack, production-ready, GPU-accelerated agentic AI platform

 

(BUSINESS WIRE)--NTT DATA, a global leader in AI, digital business and technology services, announced an initiative to deliver NVIDIA-powered enterprise AI factories that drive innovation and operational excellence for organizations worldwide. NTT DATA’s new enterprise AI factories provide full-stack, domain-specific solutions that integrate data, infrastructure, workflows and governance to give organizations a repeatable and production-ready operating model for enterprise AI.

NTT DATA enterprise AI factories, powered by NVIDIA, are adaptive, intelligent and automated ecosystems designed to help clients accelerate return on investment by scaling enterprise AI efficiently and managing the full AI lifecycle end to end. The company’s new enterprise AI factories integrate the NVIDIA AI infrastructure—combining GPU-accelerated computing and high-performance networking—with NVIDIA AI Enterprise software, including NVIDIA NIM microservices, to deliver high‑throughput, low‑latency AI that can be deployed consistently across cloud, data center and edge environments. Through NTT DATA’s advanced solutions and services, this enables scalable model training, inference and enterprise AI application development.

Building on NTT DATA’s end-to-end capabilities and deep industry expertise, the NVIDIA-powered enterprise AI factories are purpose-built to meet domain-specific requirements at industry scale. This enables organizations to drive faster innovation, optimize operations, enhance knowledge management and support data-driven decision-making while reducing risk and time to value.

“Visionary enterprises are redesigning core workflows end to end with AI, and they need trusted partners working in unison to achieve transformative and measurable results,” said Abhijit Dubey, CEO, NTT DATA, Inc. “By integrating NVIDIA technologies into our enterprise AI factories, we’re giving clients a powerful, standardized and secure environment to adopt agentic AI with measurable returns from the start.”

NTT DATA Real-World Deployments Demonstrate Measurable Impact

Early adopters are demonstrating how NTT DATA is deploying NVIDIA AI infrastructure to translate advanced AI capabilities into real-world, domain-specific impact. Examples include:

Healthcare: A leading cancer-research hospital is working with NTT DATA and Dell to use NVIDIA HGX platforms for advanced radiology analysis and rapid model evaluation, supporting clinical research and diagnostic workflows.

Automotive Manufacturing: A global automotive supplier partnered with NTT DATA to accelerate smart factory modernization using GPU as a Service powered by NVIDIA AI infrastructure. This manufacturer reduced production setup time from months to days by validating workloads on bare metal and then scaling them via an AI-factory architecture.

Technology Manufacturing: A U.S.-based advanced manufacturing company is working with NTT DATA to virtually validate a next-generation battery production line using NVIDIA-accelerated simulation and 3D visualization. Modeling material flow, automation logic and production scenarios before physical deployment reduces commissioning risk, improves throughput and establishes a scalable foundation for future digital factory expansion.

NTT DATA Integrates NVIDIA NeMo and NIM Microservices

NTT DATA also has expanded NTT DATA AI solutions by integrating NVIDIA NeMo, a modular software suite for building, customizing, and managing enterprise-scale agentic AI systems on GPU-accelerated infrastructure, and NVIDIA NIM microservices, which provide prebuilt, GPU‑optimized containers with industry‑standard APIs for fast, reliable deployment of AI applications at scale.

NTT DATA offers integrated, prequalified GenAI prototypes and solutions that standardize output, minimize complexity, reduce risk, speed adoption and accelerate return. With the integration of NeMo and NIM, NTT DATA AI solutions provide a full-stack, production-ready, GPU-accelerated AI agent platform.

“Organizations worldwide are moving from isolated model adoption to intelligent AI solutions and platforms, often complementing GenAI with agents that reason, act and adapt within enterprise systems,” said Yutaka Sasaki, President and CEO, NTT DATA Group. “Embedding NVIDIA technologies into our platforms accelerates innovation while giving clients the performance, control and compliance they require.”

“Enterprises are now seeking robust, scalable platforms that can successfully transition their AI initiatives from pilot projects to full-scale production,” said John Fanelli, Vice President, Enterprise Software, NVIDIA. “NTT DATA’s AI factory offerings, built on the NVIDIA full-stack platform, provide clients with the domain-specific solutions needed to confidently achieve production-grade enterprise AI at scale.”

NTT DATA Builds on Longstanding Foundation of Innovation with NVIDIA Technology

NTT DATA is the only global IT services provider that is active across NVIDIA’s Solution Provider, Cloud Partner and Global System Integrator Partner Network tracks. This broad and deep expertise enables NTT DATA to deliver unique full-stack services, from advisory to deployment and operations.

Learn more about NVIDIA-powered innovations from NTT DATA here. Learn more about NTT DATA’s full-stack services and solutions at nttdata.com.

About NTT DATA

NTT DATA is a $30+ billion business and technology services leader, serving 75% of the Fortune Global 100. We are committed to accelerating client success and positively impacting society through responsible innovation. We are one of the world’s leading AI and digital infrastructure providers, with unmatched capabilities in enterprise-scale AI, cloud, security, connectivity, data centers and application services. Our consulting and industry solutions help organizations and society move confidently and sustainably into the digital future. As a Global Top Employer, we have experts in more than 70 countries. We also offer clients access to a robust ecosystem of innovation centers as well as established and start-up partners. NTT DATA is part of NTT Group, which invests over $3 billion each year in R&D.

Visit us at nttdata.com.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260311112934/en/

Permalink

https://www.aetoswire.com/en/news/54444267

Contacts

Contacts

Media Contact

NTT DATA, Inc.

public.relations@nttdata.com

NTT DATA Group Corporation

Global Innovation Headquarters

Global AI Office

GAO_Global_Marketing@hml.nttdata.co.jp

SLB Provides Update on Middle East Operations and First Quarter Outlook

 

 (BUSINESS WIRE)--SLB (NYSE: SLB) continues to closely monitor the unfolding situation in the Middle East and adapt its operations.

The safety and security of SLB’s employees is the highest priority, and the company has activated local and regional crisis response teams that are meeting daily. Travel to and transit through the region have been suspended, and the company has begun to demobilize operations in a few countries in response to customer actions to safeguard personnel and facilities. These measures will continue as long as necessary until the environment in the region has stabilized. SLB is working closely with local authorities and its customers to monitor the situation and will begin a phased resumption of full activity as conditions allow.

SLB revenue for the first quarter will be lower than expected, and the company expects to incur additional costs resulting in an impact of approximately 6-9 cents of earnings per diluted share for the first quarter. Given the dynamic nature of the environment, these factors could change, and we will continue to closely monitor developments and their impact.

Despite these near-term disruptions, SLB remains confident in the underlying resilience of its global business, including the Middle East. The company has dealt with numerous geopolitical crises throughout its 100-year history and has deep experience navigating these challenges while remaining focused on serving its global customer base.

About SLB

SLB (NYSE: SLB) is a global technology company that has driven energy innovation for 100 years. With a global footprint in more than 100 countries and employees representing almost twice as many nationalities, we work each day on innovating oil and gas, delivering digital at scale, decarbonizing industries, and developing and scaling new energy systems that accelerate the energy transition. Find out more at slb.com.

Cautionary Statement Regarding Forward-looking Statements

This Form 8-K and the press release furnished as Exhibit 99 hereto, as well as other statements we make, contain “forward-looking statements” within the meaning of the federal securities laws, which include any statements that are not historical facts. Such statements often contain words such as “expect,” “may,” “can,” “believe,” “predict,” “plan,” “potential,” “projected,” “projections,” “precursor,” “forecast,” “outlook,” “expectations,” “estimate,” “intend,” “anticipate,” “ambition,” “goal,” “target,” “scheduled,” “think,” “should,” “could,” “would,” “will,” “see,” “likely,” and other similar words. Forward-looking statements address matters that are, to varying degrees, uncertain, such as statements about our financial and performance targets and other forecasts or expectations regarding, or dependent on, our business outlook; future global economic and geopolitical conditions; future liquidity, including free cash flow; and future results of operations. These statements are subject to risks and uncertainties, including, but not limited to, changing global economic and geopolitical conditions; changes in exploration and production spending by our customers, and changes in the level of oil and natural gas exploration and development; the results of operations and financial condition of our customers and suppliers; the inability to achieve our financial and performance targets and other forecasts and expectations; the inability to achieve our net-zero carbon emissions goals or interim emissions reduction goals; general economic, geopolitical, and business conditions in key regions of the world; foreign currency risk; inflation; changes in monetary policy by governments; tariffs; pricing pressure; weather and seasonal factors; unfavorable effects of health pandemics; availability and cost of raw materials; operational modifications, delays, or cancellations; challenges in our supply chain; production declines; the extent of future charges; the inability to recognize efficiencies and other intended benefits from our business strategies and initiatives, such as digital or new energy, as well as our cost reduction strategies; changes in government regulations and regulatory requirements, including those related to offshore oil and gas exploration, radioactive sources, explosives, chemicals, and climate-related initiatives; the inability of technology to meet new challenges in exploration; the competitiveness of alternative energy sources or product substitutes; and other risks and uncertainties detailed in this Form 8-K and the presentation furnished hereto and our most recent Forms 10-K, 10-Q, and 8-K filed with or furnished to the SEC.

If one or more of these or other risks or uncertainties materialize (or the consequences of any such development changes), or should our underlying assumptions prove incorrect, actual results or outcomes may vary materially from those reflected in our forward-looking statements. Statements in this Form 8-K and the press release furnished hereto are made as of the date hereof, and SLB disclaims any intention or obligation to update publicly or revise such statements, whether as a result of new information, future events, or otherwise.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260310710904/en/

Permalink

https://aetoswire.com/en/news/54444582

Contacts

 

Media

Josh Byerly – SVP of Global Communications

Moira Duff – Director of External Communications

SLB

Tel: +1 (713) 375-3407

media@slb.com

Investors

James R. McDonald – SVP of Investor Relations & Industry Affairs

Joy V. Domingo – Director of Investor Relations

SLB

Tel: +1 (713) 375-3535

investor-relations@slb.com

توسِّع IFF بصمتها في أمريكا اللاتينية عبر افتتاح مركز إنزيمات جديد ومختبر تطبيقات في البرازيل

(BUSINESS WIRE)-- تعمل IFF (المدرجة في بورصة نيويورك بالرمز: IFF) — الرائدة عالميًا في النكهات والعطور ومكونات الأغذية والعلوم البيولوجية — على تعزيز قدرات الإنتاج والابتكار الإقليمية لدعم النمو المستمر لأعمالها في مجال الصحة والعلوم البيولوجية (H&B) في أمريكا اللاتينية، إحدى أسرع الأسواق نموًا للشركة. يتضمَّن هذا المشروع تحويل موقع Arroyito في الأرجنتين إلى أول مركز إنتاج إنزيمات كامل يعتمد على التخمير لشركة IFF في المنطقة، إلى جانب افتتاح مختبر لتطبيقات العناية المنزلية في مركز الابتكار التابع للشركة في البرازيل. تساهم هذه التحسينات مجتمعة في تعزيز بصمة IFF الإقليمية، ومن المتوقع أن تُحسّن سرعة الأداء وموثوقيته، مع تقديم حلول محلية مصممة خصيصًا لأسواق التخمير، وتغذية الحيوانات، والوقود الحيوي، ومنتجات العناية المنزلية.

صرَّحت Letícia Gonçalves، رئيسة أعمال الصحة والعلوم البيولوجية في IFF قائلةً: "نحن هنا لنحوّل العلم إلى تأثير ملموس في الأماكن التي تهم أكثر". "من خلال نقل قدرات التخمير وتطبيقاتها العالمية إلى أمريكا اللاتينية، نحن نسرّع الابتكار لعملائنا ونحوّله إلى أطعمة أفضل، وحلول تنظيف أكثر فعالية، ومنتجات يومية تحسّن جودة الحياة لملايين المستهلكين في جميع أنحاء المنطقة".

 إنشاء مركز إقليمي لإنتاج الإنزيمات

 تكمن خبرة IFF العميقة في تكنولوجيا التخمير في صميم توسعة موقع Arroyito، مما يمكّن من إنتاج إنزيمات عالية الأداء من خلال عمليات بيولوجية مُتحكّم بها، تحقق نتائج متسقة تحت ظروف التصنيع الواقعية مع تقليل الأثر البيئي. بفضل هذه التحسينات، ستنتج IFF الإنزيمات محليًا ابتداءً من المرحلة البيولوجية الأولية، بدلاً من الاكتفاء بخطوات المعالجة والتغليف النهائية، ما يعزِّز موثوقية الأداء، ويزيد كفاءة المعالجة، ويسمح بإجراء التعديلات بسرعة أكبر لتلبية احتياجات العملاء المتغيرة في مجالات التخمير، وتغذية الحيوانات، والوقود الحيوي، ومنتجات العناية المنزلية.

 دفع الابتكار التطبيقي قدمًا في منتجات العناية المنزلية والشخصية

 استكمالاً لتحويل مصنع Arroyito، تم تصميم مختبر تطبيقات منتجات العناية المنزلية الجديد لشركة IFF في البرازيل لمساعدة العملاء على تقييم وتحسين أداء الإنزيمات وفقًا للظروف الإقليمية الفعلية. يدعم المختبر تطبيقات الغسيل وغسيل الصحون مما يتيح إجراء الاختبارات بسرعة أكبر، وتحسين دقة التركيبات، وتعزيز التعاون الوثيق مع العملاء الذين يطوّرون منتجات تنظيف الجيل القادم.

قالت Deia Vilela، نائبة رئيس منطقة أمريكا اللاتينية في قسم الصحة والعلوم البيولوجية بشركة IFF: "تُعدّ أمريكا اللاتينية سوقًا ديناميكيًا للنمو لحلول العلوم البيولوجية المبتكرة". "الأكثر تشويقًا هو أن هذا الزخم يتبلور عبر شراكات متينة مع العملاء والفرق في جميع أنحاء المنطقة، ما يؤسس لقاعدة قوية للابتكار المستمر والنمو المشترك في السنوات المقبلة".

استنادًا إلى أكثر من أربعة عقود من الريادة في التكنولوجيا الحيوية الصناعية، يعزّز استثمار IFF التزامها طويل الأجل تجاه المنطقة ويضع أعمالها في مجال الصحة والعلوم البيولوجية في موقع يتيح لها الاستفادة من النمو المستقبلي في أسواق الأغذية، والعناية المنزلية والشخصية، وتغذية الحيوانات، والقطاعات الصناعية الحيوية.

 بيان تحذيري بموجب قانون إصلاح التقاضي الخاص بالأوراق المالية لعام 1995

 يحتوي هذا البيان الصحفي على "تصريحات مستقبلية" وفقًا لما تحدده قوانين الأوراق المالية الفيدرالية، بما في ذلك المادة 27A من قانون الأوراق المالية، والمادة 21E من قانون بورصة الأوراق المالية لعام 1934، بصيغته المعدَّلة ("قانون البورصة"). غالبًا ما تتناول البيانات التطلعية الأداء التجاري والمالي المتوقع في المستقبل والظروف المالية، وغالبًا ما تتضمن كلمات مثل "خطة"، "توقع"، "يتوقع"، "يعتزم"، "يعتقد"، "يسعى"، "يرى"، "سوف"، "كان من الممكن"، "الهدف"، أو تعبيرات مشابهة، بالإضافة إلى صيغ هذه الكلمات بصيغتها السلبية أو المتغيرة. تتناول البيانات التطلعية بطبيعتها مسائل تتسم بدرجات متفاوتة من الشكوك، مثل البيانات المتعلقة بتوقيت أو طبيعة المنشآت الجديدة وتُقدم البيانات التطلعية الواردة في هذا البيان فقط اعتبارًا من تاريخ نشره، ولا تتحمل الشركة أي التزام بتحديث هذه البيانات التطلعية لتعكس الأحداث أو الظروف اللاحقة.

 مرحبًا بك في IFF

 في IFF (المدرجة في بورصة نيويورك بالرمز: IFF)، نصنع الفرح من خلال العلوم والإبداع والمشاعر القلبية. بصفتنا الشركة الرائدة عالميًا في مجالات النكهة، والرائحة، ومكونات الأغذية، والصحة، والعلوم البيولوجية، نحن نبتكر اليوم من أجل مستقبل أفضل. يوميًا، نقدّم حلولاً مبتكرة ومستدامة ترتقي بالمنتجات التي يعشقها الناس — تعزيزًا للصحة والرفاهية، وإثارة للحواس، وإثراء للتجربة الإنسانية. تعرَّف على المزيد على iff.com، وLinkedIn، وInstagram، وFacebook.

 ©2026 International Flavors & Fragrances Inc. (IFF). تُعدُّ IFF وشعار IFF وجميع العلامات التجارية وعلامات الخدمة المشار إليها بـ ™ أو SM أو® مملوكة لشركة IFF أو الشركات التابعة لها ما لم يتم ذكر خلاف ذلك. جميع الحقوق محفوظة.

 

صور / وسائط متعددة متوفرة على :

https://www.businesswire.com/news/home/20260310253993/en

 

إن نص اللغة الأصلية لهذا البيان هو النسخة الرسمية المعتمدة. أما الترجمة فقد قدمت للمساعدة فقط، ويجب الرجوع لنص اللغة الأصلية الذي يمثل النسخة الوحيدة ذات التأثير القانوني.

الرابط الثابت

https://aetoswire.com/ar/news/1203202653783

جهات الاتصال

علاقات الإعلام:

 Paulina Heinkel

 332.877.5339

 Media.request@iff.com

 العلاقات الاستثمارية:

 Michael Bender

 212.708.7263

 Investor.Relations@iff.com  

Galderma Buys Back Shares Worth CHF 232 Million in the Context of Accelerated Bookbuild Offering

 ZUG, Switzerland - Wednesday, 11. March 2026 AETOSWire 

Ad hoc announcement pursuant to Art. 53 LR

 

(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it has agreed to repurchase 1.6 million shares at a price of CHF 143.75 per share for a total consideration of CHF 232 million in the context of the accelerated bookbuild offering (“ABO”) of Galderma shares by Sunshine SwissCo GmbH (“EQT”), Abu Dhabi Investment Authority (Private Equities Department) and Auba Investment Pte. Ltd. (all together the “Selling Shareholders”) launched yesterday evening. The repurchase was made at the same price per share determined by the bookbuilding offering.

As a result of yesterday evening’s ABO, the Selling Shareholders have fully divested their remaining stake in Galderma.

The repurchase, which is expected to settle on March 13 is being financed by Galderma’s existing liquidity on hand and will not affect the company’s ability to deliver on its strategic and financing priorities.

The shares will be held in treasury for future use in connection with Galderma's employee participation plans, business development opportunities and/or treasury management.

 

“This repurchase reflects our confidence in Galderma’s future growth. Through our unique integrated dermatology strategy, consistent execution and financial discipline, we continue to strengthen our category leadership. This underscores our ambition to build the undisputed dermatology powerhouse, delivering attractive shareholder value creation and continuing to invest for the future.”

 

FLEMMING ØRNSKOV, M.D., MPH

CHIEF EXECUTIVE OFFICER

GALDERMA

 

Following the closing of the ABO, the free float in Galderma’s shares is expected to increase from 65% to 80%.

About Galderma

Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

Forward-looking statements

Certain statements in this announcement are forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as "plans", "targets", "aims", " believes", "expects", "anticipates", "intends", "estimates", "will", "may", "continues", "should" and similar expressions. These forward-looking statements reflect, at the time, Galderma's beliefs, intentions and current targets/ aims concerning, among other things, Galderma's results of operations, financial condition, industry, liquidity, prospects, growth and strategies and are subject to change. The estimated financial information is based on management's current expectations and is subject to change. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial consequences of the plans and events described herein. Actual results may differ from those set forth in the forward-looking statements as a result of various factors (including, but not limited to, future global economic conditions, changed market conditions, intense competition in the markets in which Galderma operates, costs of compliance with applicable laws, regulations and standards, diverse political, legal, economic and other conditions affecting Galderma’s markets, and other factors beyond the control of Galderma). Neither Galderma nor any of their respective shareholders (as applicable), directors, officers, employees, advisors, or any other person is under any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You should not place undue reliance on forward-looking statements, which speak of the date of this announcement. Statements contained in this announcement regarding past trends or events should not be taken as a representation that such trends or events will continue in the future. Some of the information presented herein is based on statements by third parties, and no representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, reasonableness, accuracy, completeness or correctness of this information or any other information or opinions contained herein, for any purpose whatsoever. Except as required by applicable law, Galderma has no intention or obligation to update, keep updated or revise this announcement or any parts thereof.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260310572494/en/

Permalink

https://www.aetoswire.com/en/news/1103202653760

Contacts

For further information:

Christian Marcoux, M.Sc.

Chief Communications Officer

christian.marcoux@galderma.com

+41 76 315 26 50

Richard Harbinson

Corporate Communications Director

richard.harbinson@galderma.com

+41 76 210 60 62

Emil Ivanov

Head of Strategy, Investor Relations, and ESG

emil.ivanov@galderma.com

+41 21 642 78 12

Jessica Cohen

Investor Relations and Strategy Director

jessica.cohen@galderma.com

+41 21 642 76 43

ATLAS Infrastructure تستثمر في H2O America وتدعم استراتيجية النمو طويلة الأجل

 سيدني ولندن - الخميس, 12. مارس 2026 أيتوس واير طباعة 

 

 ATLAS تقود جمع رأس مال H2O America وتصبح مالكًا رئيسيًا بحصة كبيرة

 تسلّط الصفقة الموسّعة الضوء على الدعم القوي في السوق لاستراتيجية H2O طويلة الأجل وتوقعات النمو الرائدة في القطاع

 تمويل كامل للنمو العضوي لشركة H2O عبر الأسهم حتى عام 20281

 

(BUSINESS WIRE)-- تُعدّ ATLAS Infrastructure (يُشار إليها باسم "ATLAS") مستثمرًا متخصصًا في البنية التحتية المدرجة عالميًا، وتدير الصناديق نيابة عن عملاء البنية التحتية طويلين الأجل. عقب الاكتتاب الأخير للأسهم، تمتلك الحسابات المُدارة بنشاط من قِبل ATLAS نحو 10.8% من الحصة التصويتية والاقتصادية في H2O America (يُشار إليها باسم "H2O").

تعبّر ATLAS عن سرورها بمساندة استراتيجية H2O طويلة الأجل للاستثمار في مرافق المياه والصرف الصحي المحلية عبر مشاركتها في الاكتتاب الأخير للأسهم. تُثمن ATLAS النهج المنضبط لإدارة H2O، الذي يركّز على الاستثمار العضوي في الأعمال القائمة إلى جانب الصفقات المستهدفة والمضافة للقيمة، مثل استحواذ Quadvest، الذي يوسّع بشكل ملموس حضور H2O في قطاع المياه الخاضع للرقابة ضمن منطقة ذات نمو مرتفع ومتميز. تدعم زيادة رأس المال الموسّعة، التي قادت ATLAS تنفيذها، استراتيجية الشركة من خلال توفير قدرة كبيرة للميزانية ومرونة مالية ممتدة ضمن خطة النفقات الرأسمالية للشركة للفترة 2026–2030.

"يُعدّ زيادة الاستثمار في مرافق المياه أمرًا ضروريًا لضمان استمرار تمتع المجتمعات بمياه شرب عالية الجودة، ولضمان تحسين شبكات الصرف الصحي لتلبية وتجاوز المتطلبات البيئية بالتوازي مع تزايد السكان. تعبّر ATLAS عن سرورها بدعم إدارة وموظفي H2O عبر الاكتتاب الأخير للأسهم، بما يضمن تمتع الشركة بالقدرة المالية اللازمة لمواصلة استراتيجيتها في الاستثمار وتطوير شبكاتها وخدماتها. يتوافق هذا الاستثمار المتزايد في H2O بشكل جيد مع هدف ATLAS المتمثل في تحقيق عوائد مستدامة طويلة الأجل لعملائنا من خلال الاستثمار في شركات بنية تحتية عالية الجودة تستثمر في تقديم الخدمات الأساسية لمجتمعاتها المحلية".

- Rod Chisholm، شريك

تقديرات ATLAS

إن نص اللغة الأصلية لهذا البيان هو النسخة الرسمية المعتمدة. أما الترجمة فقد قدمت للمساعدة فقط، ويجب الرجوع لنص اللغة الأصلية الذي يمثل النسخة الوحيدة ذات التأثير القانوني.

 

الرابط الثابت

https://www.aetoswire.com/ar/news/544425471

جهات الاتصال

 للمزيد من المعلومات حول هذا البيان، يُرجى التواصل مع ATLAS Infrastructure على:

info@atlasinfrastructure.com أو تفضَّل بزيارة www.atlasinfrastructure.com

ATLAS Infrastructure Invests in H2O America, Backs Long-Term Growth Strategy

 

SYDNEY& LONDON - Wednesday, 11. March 2026 AETOSWire Print 

ATLAS anchors H2O America’s equity raise and establishes new substantial shareholding

Upsized transaction highlights strong market support for H2O’s long-term strategy and sector leading growth outlook

H2O’s organic growth fully equity funded into 20281

 

(BUSINESS WIRE)--ATLAS Infrastructure (“ATLAS”) is a specialist Global Listed Infrastructure investor managing funds on behalf of long-term infrastructure clients. Following the recent equity placement, ATLAS’s actively managed accounts hold ~10.8% voting and economic interest in H2O America (“H2O”).

ATLAS was pleased to support H2Os long‑term strategy to invest in local water and wastewater utility operations through our participation in the recent equity raise. ATLAS recognises the disciplined approach from H2O management which focuses on organic investment in existing businesses alongside targeted and accretive transactions such as the acquisition of Quadvest which materially expands H2O’s regulated water footprint in a premium high‑growth jurisdiction. The upsized equity raise, anchored by ATLAS, supports the company strategy through providing significant balance sheet capacity and financial flexibility well into the Company’s 2026-2030 CapEx plan.

“Increased investment in water utilities is essential to ensure that communities can continue to enjoy high quality drinking water and that wastewater networks can continue to improve to meet and exceed environmental expectations alongside a growing population. ATLAS is pleased to support the management and employees of H2O through this equity placement by ensuring that the company has the capital support to continue its strategy of investment and improvements to its network and services. This increased investment into H2O fits well with the ATLAS objective of delivering long term, sustainable returns for our clients through investment in high quality infrastructure companies that are investing in delivering essential services to their local communities.”

- Rod Chisholm, Partner

1. ATLAS estimates

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260309037799/en/

Permalink

https://www.aetoswire.com/en/news/54442547

Contacts

 

For more information regarding this release contact ATLAS Infrastructure at:

info@atlasinfrastructure.com or visit www.atlasinfrastructure.com

Le bénéfice net d’Estithmar Holding bondit de 122 % pour atteindre 938 millions de QAR ; le chiffre d’affaires progresse de 54 % à 6,4 milliards de QAR pour l’exercice clos le 31 décembre 2025.

Doha, Qatar - mercredi, 11. mars 2026

Croissance durable portée par l’expansion internationale

Hausse significative des principaux indicateurs financiers

 

Estithmar Holding Q.P.S.C. a annoncé ses résultats financiers pour l’exercice clos le 31 décembre 2025. Le groupe a enregistré une hausse de 54 % de son chiffre d’affaires, atteignant 6,4 milliards de riyals qataris, contre 4,2 milliards en 2024. Le bénéfice brut s’est élevé à 2,1 milliards de riyals qataris, contre 1 milliard en 2024, soit une croissance de 111 %. L’EBITDA a atteint 1,5 milliard de riyals qataris, en hausse de 102 % sur un an.

 

Le bénéfice net a progressé de 122 % par rapport à 2024, pour atteindre 938 millions de riyals qataris. Le bénéfice par action a augmenté de 145 %, s’établissant à 0,264 riyals qataris.

 

La croissance du bénéfice net a été principalement portée par l’augmentation des revenus, en particulier dans les secteurs de la construction spécialisée et de la santé. Les résultats reflètent la capacité du groupe à transformer sa croissance opérationnelle en une rentabilité durable tout en maintenant une discipline financière.

 

Le total des actifs a augmenté de 23 % en 2025 par rapport à l’année précédente, principalement grâce à de nouveaux projets ajoutés au portefeuille d’Estithmar Holding, dont l’Hôpital international de Bagdad en Irak.

 

Le Conseil d’administration a recommandé la distribution de dividendes équivalents à 20 % du capital social de la société, sous forme de 2 actions gratuites pour chaque tranche de 10 actions détenues.

 

Les résultats de 2025 montrent une nette amélioration des principaux indicateurs financiers, soutenue par l’expansion dans les secteurs clés du groupe, une meilleure exécution des projets et une efficacité opérationnelle accrue dans l’ensemble de ses activités. Ces résultats démontrent la capacité d’Estithmar Holding à développer ses opérations tout en maintenant une discipline financière et en renforçant sa rentabilité.

 

Commentant ces résultats, Juan Leon, PDG d’Estithmar Holding, a déclaré : « L’année 2025 représente une étape importante dans le parcours d’Estithmar Holding. Notre solide performance financière reflète la mise en œuvre réussie de notre stratégie de croissance et d’expansion dans les différents secteurs du groupe, ainsi que les efforts considérables de nos équipes sur plusieurs marchés ».

 

« La réalisation d’une forte croissance sur l’ensemble des principaux indicateurs financiers souligne la solidité de notre modèle d’affaires diversifié, ainsi que notre engagement constant en faveur de l’excellence opérationnelle, du maintien de la discipline financière et de la bonne gouvernance. À mesure que nous élargissons notre empreinte et renforçons notre présence sur les marchés régionaux, nous restons déterminés à créer une valeur durable pour nos actionnaires tout en explorant de nouvelles opportunités de croissance ».                                                                                                                                          

« La solide position financière du groupe nous permet d’aller de l’avant avec les initiatives stratégiques à venir, tout en évaluant de potentielles opportunités sur les marchés de capitaux afin de soutenir la prochaine phase d’expansion du groupe », a ajouté Leon.

 

Le groupe de construction spécialisée a généré la plus grande part du chiffre d'affaires total de l'entreprise en 2025. Le secteur a enregistré une forte activité tant au niveau local que régional, en particulier en Arabie saoudite, en Syrie, en Algérie et en Irak. Au cours de l’année, les divisions industrielles et de construction spécialisée de l’entreprise ont poursuivi leur expansion, en exécutant des projets majeurs dans 12 pays. Parmi ceux-ci figurent des développements de grande envergure, tels que les projets de la mer Rouge en Arabie saoudite, des projets d’infrastructures en Syrie, ainsi que plusieurs développements majeurs au Qatar, notamment dans le domaine des infrastructures éducatives.

 

Au cours de l’année, le groupe a obtenu 262 nouveaux contrats, reflétant la confiance croissante accordée à ses sociétés en tant que partenaires pour la réalisation de projets majeurs.

 

Le groupe de santé d’Estithmar Holding, à travers sa filiale Apex Health, a également poursuivi une croissance durable, portée par la mise en œuvre de son modèle régional de gestion et d’exploitation hospitalière, notamment en Irak et en Libye.

 

Au Qatar, les hôpitaux du groupe — The View Hospital et le Korean Medical Center — ont continué de renforcer la confiance des patients grâce au respect des normes internationales de qualité les plus élevées et à l’accueil de médecins de renommée mondiale. En 2025, The View Hospital a réalisé plus de 100 chirurgies robotisées.

 

Lire la suite.

 

La seule version du communiqué qui fasse foi est celle du communiqué dans sa langue d’origine. La traduction devra toujours être confrontée au texte source, qui fera jurisprudence.

Permalink

https://www.aetoswire.com/fr/news/1103202653778

Contacts

Nesrine Nacef

Responsable de la communication institutionnelle

0097466157504

IFF Expands Latin American Footprint With New Enzyme Hub, Brazil Application Lab

 

 (BUSINESS WIRE)--IFF (NYSE: IFF) — a global leader in flavors, fragrances, food ingredients and health & biosciences — is enhancing regional production and innovation capabilities to better support the continued growth of its Health & Biosciences (H&B) business in Latin America, one of the fastest-growing markets for the company. The effort includes the transformation of the Arroyito site in Argentina into IFF’s first full fermentation‑based enzyme production hub in the region and the opening of a household care application laboratory at IFF’s Innovation Center in Brazil. Together, these enhancements expand IFF’s regional footprint and are expected to improve speed, reliability and locally relevant solutions for markets including brewing, animal nutrition, biofuels and home care.

“This is about turning science into impact where it matters most,” said Letícia Gonçalves, president of IFF H&B. “By bringing world‑class fermentation and application capabilities to Latin America, we are accelerating innovation for our customers and translating that into better food, more effective cleaning solutions and everyday products that improve quality of life for millions of consumers across the region.”

Building a regional enzyme production hub

IFF’s deep expertise in fermentation technology is at the heart of the Arroyito expansion, enabling the production of high‑performance enzymes through controlled biological processes that deliver consistent results under real‑world manufacturing conditions while reducing environmental impact. With the enhancements, IFF will now produce enzymes locally from the initial biological stage rather than relying solely on final processing and packaging steps, improving performance reliability, increasing processing efficiency and enabling faster adjustments as customer needs evolve across applications including brewing, animal nutrition, biofuels and home care.

Advancing applied innovation in home and personal Care

Complementing the Arroyito plant transformation, IFF’s new household care application laboratory in Brazil is designed to help customers evaluate and optimize enzyme performance under real regional conditions. The laboratory supports laundry and dishwashing applications, enabling faster testing, improved formulation accuracy and closer collaboration with customers developing next‑generation cleaning products.

“Latin America is a dynamic growth market for bioscience‑enabled solutions,” said Deia Vilela, vice president of Latin America for IFF H&B. “What’s most exciting is how this momentum is being shaped through deeper partnerships with customers and teams across the region, creating a strong foundation for sustained innovation and shared growth in the years ahead.”

Building on more than four decades of industrial biotechnology leadership, IFF’s investment reinforces its long‑term commitment to the region and positions its Health & Biosciences business to capture future growth across food, home and personal care, animal nutrition and bio‑industrial markets.

Cautionary Statement under the Private Securities Litigation Reform Act of 1995

This press release contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as “”plan”, “expect,” “anticipate,” “intend,” “believe,” “seek,” “see,” “will,” “would,” “target,” similar expressions, and variations or negatives of these words. Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements about the timing or nature of the new facilities. The forward-looking statements included in this release are made only as of the date hereof, and we undertake no obligation to update the forward-looking statement to reflect subsequent events or circumstances.

Welcome to IFF

At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in taste, scent, food ingredients, health and biosciences, we’re innovating for the future. Every day, we deliver groundbreaking, sustainable solutions that elevate products people love — advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook.

©2026 International Flavors & Fragrances Inc. (IFF). IFF, the IFF Logo, and all trademarks and service marks denoted with ™, SM or ® are owned by IFF or affiliates of IFF unless otherwise noted. All Rights Reserved.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260310253993/en/

Permalink

https://aetoswire.com/en/news/1103202653755

Contacts

Media Relations:

Paulina Heinkel

332.877.5339

Media.request@iff.com

Investor Relations:

Michael Bender

212.708.7263

Investor.Relations@iff.com

 

Chiesi and Bespak Partner to Advance Carbon Minimal Inhaler Production With UK Manufacturing Site

 PARMA, Italy & HOLMES CHAPEL, England - Wednesday, 11. March 2026 AETOSWire  

Highlights

Agreement builds on existing Chiesi-Bespak collaboration, reinforcing a trusted relationship as Chiesi works to evolve a portfolio of extrafine formulation Carbon Minimal Inhalers1, ensuring patients retain continuity of care while reducing carbon emissions

Bespak’s leadership in low-GWP propellant inhaler manufacturing along with significant expansion at its Holmes Chapel site strengthens Chiesi’s global supply chain resilience

Partnership aligns with the science-based climate commitments of both companies

 

(BUSINESS WIRE)--Chiesi Group ("Chiesi"), the international research focused biopharmaceutical company and a certified B Corp, and Bespak, the specialist inhalation CDMO focused on pulmonary and nasal drug delivery, today announced an expansion of their long-standing partnership, increasing pressurized metered dose inhaler (pMDI) manufacturing capacity at Bespak’s Holmes Chapel site to support the next phase of Chiesi’s Carbon Minimal Inhaler (CMI) program.

Building on years of collaboration, the agreement reflects a shared long-term vision: delivering lower carbon inhaled therapies through CMIs at scale, without compromising clinical choice or continuity of care for patients. Both companies are committed to addressing climate change through measurable, science-based action. Chiesi’s ambition to reach Net Zero targets by 2035, and Bespak’s validated decarbonization roadmap, underpin a partnership grounded in shared sustainability principles.

Maria Paola Chiesi, Chiesi Group Vice Chair, said: “At Chiesi, sustainability is not an add-on; it is a commitment that guides our strategic choices. We know that inhalers are essential treatments, and that the environmental impact associated with them must be addressed without shifting the burden onto patients. The partnership with Bespak reinforces our efforts to reduce emissions across the value chain, while protecting access, quality and trust. Climate action and patient care must continue to advance hand in hand.”

To meet the needs of patients and reduce impact on the environment, Chiesi is working to be the only company to offer a portfolio of extrafine formulation Carbon Minimal Inhalers, including both dry powder inhalers (DPIs) and next generation propellant pMDIs. Chiesi’s CMI program is designed to significantly reduce the carbon footprint of pMDIs by up to 90%, through the transition to a next-generation, low global warming potential (GWP) propellant, while maintaining established treatment options and device familiarity for patients. Reinforcing the partnership with Bespak adds industrial scale and resilience to Chiesi’s journey, supporting a phased and responsible transition.

The expanded collaboration further strengthens Bespak’s position at the forefront of the global industry’s transition to next-generation, low-GWP propellants, and its Holmes Chapel site as a specialist pMDI manufacturing hub within the global pharmaceutical supply chain. Positioned in the North West of England’s inhalation R&D and manufacturing cluster, the site contributes high value skills, advanced technical expertise and long-term investment in sustainable inhaler manufacturing, for the benefit of patients and healthcare systems worldwide.

Giuseppe Accogli, Chiesi Group CEO, added: “This agreement strengthens an already established partnership with Bespak, and is a concrete example of how we translate our ambition into action. By working with trusted partners across our value chain, we can deliver sustainable innovation at scale while ensuring that patients receive their needed therapies.”

Chris Hirst, Bespak CEO, said: “Our collaboration with Chiesi has grown over time around a shared commitment to patient safety, technical excellence and sustainability. By deepening this partnership, we are accelerating the transition to low carbon pMDIs and reinforcing the UK’s role as a center of excellence for sustainable inhalation manufacturing. This is a position being recognized by the wider industry, leading to our Holmes Chapel site being selected as a key source of supply by leading brand owners like Chiesi, cementing our role as a strategic supply chain partner for the next generation propellant inhalers and innovative nasally-delivered therapies.”

About Chiesi Group

Chiesi is a research-oriented international biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company’s mission is to improve people’s quality of life and act responsibly towards both the community and the environment. By adopting the legal form of Benefit Corporation in Italy, the US, France and Colombia, Chiesi’s commitment to creating shared value for society as a whole is legally binding and central to company-wide decision-making. As a certified B Corp since 2019, Chiesi is part of a global community of businesses that meet high standards of social and environmental impact. The company aims to reach Net-Zero greenhouse gases (GHG) emissions by 2035. With 90 years of experience, Chiesi is headquartered in Parma (Italy), with 31 affiliates worldwide, and counts more than 7,500 employees. The Group’s research and development center in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden.

For more information, visit chiesi.com or the website of your local Chiesi affiliate.

About Bespak

Bespak is a specialist inhalation contract development and manufacturing organisation (CDMO) focused on pulmonary and nasal drug delivery. Trusted by the world’s leading pharmaceutical companies, Bespak delivers end-to-end capabilities across product development, clinical supply and commercial manufacturing of inhaled therapies for global supply.

Headquartered in Holmes Chapel, UK, with specialist manufacturing sites in Holmes Chapel and King’s Lynn, UK, Bespak develops and supplies pressurised metered dose inhaler (pMDI) products, valves and actuators, complex dry powder inhaler (DPI) devices, nasal products and devices, and supports emerging inhalation technologies, including innovative soft mist systems.

Sustainability underpins every step of how Bespak operates and innovates. The company has taken clear and measurable steps to align with key United Nations (UN) Sustainable Development Goals (SDGs), is a signatory of the United Nations Global Compact (UNGC) and has set approved net-zero and near-term company-wide emissions targets with the Science Based Targets initiative (SBTi).

Through collaboration and targeted investment, Bespak is accelerating the industry’s transition to more sustainable inhaled medicines.

Built on a long history of inhalation experience and ready for the future, Bespak is a long-term innovation partner creating lasting impact for patients and the planet.

_________________________ 

1 In a limited number of countries, including the United Kingdom, non‑extrafine products will also be transitioned to CMI.

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260311319953/en/

Permalink

https://www.aetoswire.com/en/news/54443982

Contacts

 

Press Info:

Chiesi Group

Anna Bonisoli Alquati, Head of Global External Communications, mediarelations@chiesi.com

Michela Lijoi, Global External Communications Sr. Manager: mobile +39 328.6353044, e-mail: m.lijoi@chiesi.com

Bespak

For further information and interview opportunities, please contact:

Notch Communications Ltd: e-mail: bespak@notchcommunications.co.uk